How does cancer cell metabolism affect tumor migration and invasion?

Cell Adhesion and Migration

Volumn 7, Issue 5, 2013, Pages 395-403

  Han, Tianyu ^a   Kang, De ^a   Ji, Daokun ^a   Wang, Xiaoyu ^a   Zhan, Weihua ^a   Fu, Mingui ^a   Xin, Hong Bo ^a   Wang, Jian Bin ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Cancer cell metabolism; Cell migration; Glutamine; Glycolysis; Metastasis

Indexed keywords

GLUTAMINE;

AMINO ACID METABOLISM; CANCER CELL; CANCER PATIENT; CELL INVASION; CELL METABOLISM; CELL MIGRATION; GLYCOLYSIS; HUMAN; METASTASIS; PENTOSE PHOSPHATE CYCLE; REVIEW; SIGNAL TRANSDUCTION;

CANCER CELL METABOLISM; CELL MIGRATION; GLUTAMINE; GLYCOLYSIS; METASTASIS;

CELL MOVEMENT; CELL PROLIFERATION; GLYCOLYSIS; HUMANS; MITOCHONDRIA; NEOPLASM INVASIVENESS; NEOPLASMS; OXIDATIVE STRESS; STROMAL CELLS;

EID: 84891846840     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.26345     Document Type: Review

References (111)

1. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2:563-72; PMID:12154349; http://dx.doi.org/10.1038/nrc865
2. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011; 147:992-1009; PMID:22118458; http://dx.doi.org/10.1016/j.cell.2011.11.016
3. Servant G, Weiner OD, Herzmark P, Balla T, Sedat JW, Bourne HR. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science 2000; 287:1037-40; PMID:10669415; http://dx.doi.org/10.1126/science. 287.5455.1037
4. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. J Gen Physiol 1927; 8:519-30; PMID:19872213; http://dx.doi.org/10.1085/jgp.8.6.519
5. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11:325-37; PMID:21508971; http://dx.doi.org/10.1038/nrc3038
6. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21:297-308; PMID:22439925; http://dx.doi.org/10.1016/j.ccr.2012.02.014
7. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 2003; 63:3847-54; PMID:12873971
8. Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 1999; 18:3199-204; PMID:10359525; http://dx.doi.org/10.1038/sj.onc.1202660
9. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001; 69:522-30; PMID:11310837
10. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007; 17:71-7; PMID:17208433; http://dx.doi.org/10.1016/j.gde.2006.12.006
11. Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S. Hypoxia-induced dedifferentiation of tumor cells - a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 2005; 16:554-63; PMID:16144692; http://dx.doi.org/10.1016/j.semcdb.2005.03.007
12. O'Rourke JF, Pugh CW, Bartlett SM, Ratcliffe PJ. Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur J Biochem 1996; 241:403-10; PMID:8917436; http://dx.doi.org/10.1111/j.1432-1033.1996.00403.x
13. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269:23757-63; PMID:8089148
14. Huang LE. Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell Death Differ 2008; 15: 672-7; PMID:18188166; http://dx.doi.org/10.1038/sj.cdd.4402302
15. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15:6479-83; http://dx.doi.org/10.1158/1078-0432.CCR-09-0889; PMID:19861459
16. Fan TW, Kucia M, Jankowski K, Higashi RM, Ratajczak J, Ratajczak MZ, Lane AN. Rhabdomyosarcoma cells show an energy producing anabolic metabolic phenotype compared with primary myocytes. Mol Cancer 2008; 7:79; PMID:18939998; http://dx.doi.org/10.1186/1476-4598-7-79
17. Shi Q, Le X, Wang B, Abbruzzese JL, Xiong Q, He Y, Xie K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 2001; 20:3751-6; PMID:11439338; http://dx.doi.org/10.1038/sj.onc. 1204500
18. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011; 2:49; http://dx.doi.org/10.3389/fphar.2011.00049; PMID:21904528
19. Kato Y, Ozawa S, Tsukuda M, Kubota E, Miyazaki K, St-Pierre Y, Hata R. Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma. FEBS J 2007; 274:3171-83; PMID:17540003; http://dx.doi.org/10.1111/j.1742-4658.2007.05848.x
20. rd, Petty HR. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator. Histochem Cell Biol 2004; 121:299-310; PMID:15042374; http://dx.doi.org/10.1007/s00418-004-0639-3
21. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 2001; 61:3493-500; PMID:11309313
22. Tedone T, Correale M, Barbarossa G, Casavola V, Paradiso A, Reshkin SJ. Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion. FASEB J 1997; 11:785-92; PMID:9271363
23. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6:764-75; PMID:16990854; http://dx.doi.org/10.1038/ nrc1949
24. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006; 66:5216-23; PMID:16707446; http://dx.doi.org/10.1158/0008-5472.CAN-05-4193
25. Goetze K, Walenta S, Ksiazkiewicz M, Kunz-Schughart LA, Mueller-Klieser W. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol 2011; 39:453-63; PMID:21617859
26. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000; 60:916-21; PMID:10706105
27. Yokota H, Guo J, Matoba M, Higashi K, Tonami H, Nagao Y. Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer. J Magn Reson Imaging 2007; 25:992-9; PMID:17410583; http://dx.doi.org/10.1002/jmri.20902
28. Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA. Lactate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. FASEB J 2007; 21:2602-12; PMID:17395833; http://dx.doi.org/10.1096/ fj.07-8174com
29. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277:23111-5; PMID:11943784; http://dx.doi.org/10.1074/jbc.M202487200
30. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005; 280:41928-39; PMID:16223732; http://dx.doi.org/ 10.1074/jbc.M508718200
31. Brahimi-Horn C, Pouysségur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006; 93:E73-80; PMID:16935775
32. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187
33. Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441:437-43; PMID:16724055; http://dx.doi.org/10.1038/nature04871
34. Enns L, Ladiges W. Mitochondrial redox signaling and cancer invasiveness. J Bioenerg Biomembr 2012; 44:635-8; PMID:22886605; http://dx.doi.org/10.1007/ s10863-012-9467-7
35. Caneba CA, Bellance N, Yang L, Pabst L, Nagrath D. Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis, mitochondrial function, and migration. Am J Physiol Endocrinol Metab 2012; 303:E1036-52; PMID:22895781; http://dx.doi.org/10.1152/ajpendo. 00151.2012
36. Achari A, Marshall SE, Muirhead H, Palmieri RH, Noltmann EA. Glucose-6-phosphate isomerase. Philos Trans R Soc Lond B Biol Sci 1981; 293:145-57; PMID:6115414; http://dx.doi.org/10.1098/rstb.1981.0068
37. Watanabe H, Takehana K, Date M, Shinozaki T, Raz A. Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996; 56:2960-3; PMID:8674049
38. Shimizu K, Tani M, Watanabe H, Nagamachi Y, Niinaka Y, Shiroishi T, Ohwada S, Raz A, Yokota J. The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 1999; 456:295-300; PMID:10456327; http://dx.doi.org/10.1016/S0014-5793(99)00966-7
39. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 2003; 107:707-14; PMID:14566819; http://dx.doi.org/10.1002/ijc.11449
40. Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res 2004; 10:7775-84; PMID:15570012; http://dx.doi.org/10.1158/1078-0432.CCR-04-1015
41. Araki K, Shimura T, Yajima T, Tsutsumi S, Suzuki H, Okada K, Kobayashi T, Raz A, Kuwano H. Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem 2009; 284:32305-11; PMID:19801670; http://dx.doi.org/10.1074/jbc.M109.008250
42. Norgauer J, Metzner B, Schraufstätter I. Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol 1996; 156:1132-7; PMID:8557989
43. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003; 22:256-65; PMID:12527894; http://dx.doi.org/10.1038/sj.onc.1206113
44. Tsutsumi S, Gupta SK, Hogan V, Collard JG, Raz A. Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res 2002; 62:4484-90; PMID:12154059
45. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-54; PMID:12189386; http://dx.doi.org/10.1038/nrc822
46. Wang JM, Taraboletti G, Matsushima K, Van Damme J, Mantovani A. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun 1990; 169:165-70; PMID:2190552; http://dx.doi.org/10.1016/0006-291X(90)91449-3
47. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66:8319-26; PMID:16951136; http://dx.doi.org/10.1158/0008-5472.CAN-06-0410
48. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005; 6:622-34; PMID:16025097; http://dx.doi.org/10.1038/ nrm1699
49. Perona R, Montaner S, Saniger L, Sánchez-Pérez I, Bravo R, Lacal JC. Activation of the nuclear factorkappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 1997; 11:463-75; PMID:9042860; http://dx.doi.org/10.1101/ gad.11.4.463
50. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114:569-81; PMID:15314694
51. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W, Sarkar FH, Raz A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011; 71:3400-9; PMID:21389093; http://dx.doi.org/10.1158/0008-5472. CAN-10-0965
52. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007; 26:711-24; PMID:16862183; http://dx.doi.org/10.1038/sj. onc.1209808
53. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, Lin Y, Yao J, Shi J, Kang T, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 2013; 23:316-31; PMID:23453623; http://dx.doi.org/10.1016/j.ccr.2013.01.022
54. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 2011; 43:969-80; PMID:20156581; http://dx.doi.org/10.1016/j.biocel.2010.02.005
55. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15:300-8; PMID:15908230; http://dx.doi.org/10.1016/j.semcancer.2005.04.009
56. Wang LY, Liu YP, Chen LG, Chen YL, Tan L, Liu JJ, Jazag A, Ren JL, Guleng B. Pyruvate kinase M2 plays a dual role on regulation of the EGF/EGFR signaling via E-cadherin-dependent manner in gastric cancer cells. PLoS One 2013; 8:e67542; PMID:23840737; http://dx.doi.org/10.1371/journal.pone.0067542
57. Zhou CF, Li XB, Sun H, Zhang B, Han YS, Jiang Y, Zhuang QL, Fang J, Wu GH. Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. IUBMB Life 2012; 64:775-82; PMID:22807066; http://dx.doi.org/10.1002/iub.1066
58. Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 1996; 9:1736-42; PMID:8866602; http://dx.doi.org/10.1183/09031936.96.09081736
59. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 2005; 22:25-30; PMID:16132575; http://dx.doi.org/10.1007/s10585-005-2343-7
60. Dhup S, Dadhich RK, Porporato PE, Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr Pharm Des 2012; 18:1319-30; PMID:22360558; http://dx.doi.org/10.2174/138161212799504902
61. Baumann F, Leukel P, Doerfelt A, Beier CP, Dettmer K, Oefner PJ, Kastenberger M, Kreutz M, Nickl-Jockschat T, Bogdahn U, et al. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol 2009; 11:368-80; PMID:19033423; http://dx.doi.org/10.1215/15228517-2008-106
62. Wick W, Naumann U, Weller M. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des 2006; 12:341-9; PMID:16454748; http://dx.doi.org/10.2174/138161206775201901
63. Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 1997; 110:2473-82; PMID:9410885
64. Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bogdahn U, Hau P. The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 2007; 96:1560-8; PMID:17453002; http://dx.doi.org/10.1038/sj.bjc.6603766
65. Deryugina EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001; 263:209-23; PMID:11161720; http://dx.doi.org/10.1006/excr.2000.5118
66. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V) beta(3) integrin expression. Biochem Biophys Res Commun 2000; 268:607-11; PMID:10679251; http://dx.doi.org/ 10.1006/bbrc.2000.2176
67. Kim JH, Kim EL, Lee YK, Park CB, Kim BW, Wang HJ, Yoon CH, Lee SJ, Yoon G. Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects. Exp Cell Res 2011; 317:1108-18; PMID:21356207; http://dx.doi.org/10.1016/j.yexcr.2011.02.011
68. Bartrons R, Caro J. Hypoxia, glucose metabolism and the Warburg's effect. J Bioenerg Biomembr 2007; 39:223-9; PMID:17661163; http://dx.doi.org/10.1007/ s10863-007-9080-3
69. Dang CV. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Foundation symposium proceedings 2007:35-53.
70. Eagle H. The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture. J Exp Med 1955; 102:37-48; PMID:14392239; http://dx.doi.org/10.1084/jem.102.1.37
71. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104:19345-50; PMID:18032601; http://dx.doi.org/10.1073/pnas.0709747104
72. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18:207-19; PMID:20832749; http://dx.doi.org/10.1016/j.ccr.2010.08.009
73. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458:762-5; PMID:19219026; http://dx.doi.org/10.1038/nature07823
74. Fu YM, Zhang H, Ding M, Li YQ, Fu X, Yu ZX, Meadows GG. Specific amino acid restriction inhibits attachment and spreading of human melanoma via modulation of the integrin/focal adhesion kinase pathway and actin cytoskeleton remodeling. Clin Exp Metastasis 2004; 21:587-98; PMID:15787096; http://dx.doi.org/10.1007/s10585-004-5515-y
75. Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H, Miwa A, Kurihara H, Nakazato Y, Tamura M, et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 2002; 8:971-8; PMID:12172541; http://dx.doi.org/10.1038/nm746
76. Herner A, Sauliunaite D, Michalski CW, Erkan M, De Oliveira T, Abiatari I, Kong B, Esposito I, Friess H, Kleeff J. Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int J Cancer 2011; 129:2349-59; http://dx.doi.org/10.1002/ijc.25898; PMID:21207374
77. Rzeski W, Ikonomidou C, Turski L. Glutamate antagonists limit tumor growth. Biochem Pharmacol 2002; 64:1195-200; PMID:12234599; http://dx.doi.org/ 10.1016/S0006-2952(02)01218-2
78. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136:521-34; PMID:19203585; http://dx.doi.org/10.1016/j.cell.2008.11.044
79. Fuchs BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 2007; 293:C55-63; PMID:17329400; http://dx.doi.org/10.1152/ajpcell.00330.2006
80. Zhou H, Huang S. mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr 2010; 20:1-16; PMID:20528734; http://dx.doi.org/10.1615/CritRevEukarGeneExpr.v20.i1.10
81. Wedel S, Hudak L, Seibel JM, Makarević J, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 2011; 28:479-91; PMID:21452015; http://dx.doi.org/10.1007/s10585-011- 9386-8
82. Chen SM, Liu JL, Wang X, Liang C, Ding J, Meng LH. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. Biochem Pharmacol 2012; 83:1183-94; PMID:22305748; http://dx.doi.org/10.1016/j.bcp.2012.01.019
83. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012; 481:385-8; PMID:22101431
84. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 2011; 108:19611-6; PMID:22106302; http://dx.doi.org/10.1073/pnas.1117773108
85. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005; 24:3574-82; PMID:15806173; http://dx.doi.org/10.1038/sj.onc.1208463
86. Shih MC, Chen JY, Wu YC, Jan YH, Yang BM, Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M, et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 2012; 31:2389-400; PMID:21996732; http://dx.doi.org/10.1038/onc.2011. 419
87. Walker L, Millena AC, Strong N, Khan SA. Expression of TGFβ3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway. Clin Exp Metastasis 2013; 30:13-23; PMID:22678424; http://dx.doi.org/10.1007/s10585-012-9494-0
88. Forbes NS, Meadows AL, Clark DS, Blanch HW. Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metab Eng 2006; 8:639-52; PMID:16904360; http://dx.doi.org/10.1016/j. ymben.2006.06.005
89. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006; 25:4675-82; PMID:16892081; http://dx.doi.org/10.1038/sj.onc.1209594
90. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8:143-53; PMID:16098467; http://dx.doi.org/10.1016/j.ccr.2005.06.017
91. Sudarshan S, Shanmugasundaram K, Naylor SL, Lin S, Livi CB, O'Neill CF, Parekh DJ, Yeh IT, Sun LZ, Block K. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion. PLoS One 2011; 6:e21037; PMID:21695080; http://dx.doi.org/10.1371/journal.pone.0021037
92. Shen SH, Kwan AL, Chen YY, Wang ZX. Effect of silencing HIF-1α on proliferation, invasion and migration of glioblastoma U87 cells. Neurol Sci 2013; 34:365-71; http://dx.doi.org/10.1007/s10072-012-1010-4; PMID:22454035
93. Szeliga M, Obara-Michlewska M. Glutamine in neoplastic cells: focus on the expression and roles of glutaminases. Neurochem Int 2009; 55:71-5; PMID:19428809; http://dx.doi.org/10.1016/j.neuint.2009.01.008
94. Szeliga M, Obara-Michlewska M, Matyja E, Łazarczyk M, Lobo C, Hilgier W, Alonso FJ, Márquez J, Albrecht J. Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. Glia 2009; 57:1014-23; PMID:19062176; http://dx.doi.org/10.1002/glia.20825
95. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A 2010; 107:7455-60; PMID:20378837; http://dx.doi.org/10.1073/pnas. 1001006107
96. Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 2012; 23:362-9; PMID:22349059; http://dx.doi.org/10.1016/j.semcdb.2012.02.002
97. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem 2012; 287:11070-81; PMID:22275356; http://dx.doi.org/10.1074/jbc.M111.302547
98. Ma Z, Vocadlo DJ, Vosseller K. Hyper-OGlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem 2013; 288:15121-30; PMID:23592772; http://dx.doi.org/10.1074/jbc.M113. 470047
99. Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, Alken P, Coy JF. Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 2008; 122:2422-8; http://dx.doi.org/10.1002/ijc.23403; PMID:18302154
100. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 2012; 53:421-36; PMID:22580150; http://dx.doi.org/10.1016/j. freeradbiomed.2012.05.006
101. rd, Felding-Habermann B. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007; 67:1472-86; PMID:17308085; http://dx.doi.org/10.1158/0008-5472.CAN-06-3137
102. Schneider S, Lüdtke S, Schröder-Tittmann K, Wechsler C, Meyer D, Tittmann K. A δ38 deletion variant of human transketolase as a model of transketolase-like protein 1 exhibits no enzymatic activity. PLoS One 2012; 7:e48321; PMID:23118983; http://dx.doi.org/10.1371/journal.pone.0048321
103. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006; 94:578-85; PMID:16465194; http://dx.doi.org/10. 1038/sj.bjc.6602962
104. Földi M, Stickeler E, Bau L, Kretz O, Watermann D, Gitsch G, Kayser G, Zur Hausen A, Coy JF. Transketolase protein TKTL1 overexpression: A potential biomarker and therapeutic target in breast cancer. Oncol Rep 2007; 17:841-5; PMID:17342325
105. Schultz H, Kähler D, Branscheid D, Vollmer E, Zabel P, Goldmann T. TKTL1 is overexpressed in a large portion of non-small cell lung cancer specimens. Diagn Pathol 2008; 3:35; PMID:18700018; http://dx.doi.org/10.1186/ 1746-1596-3-35
106. Xu X, Zur Hausen A, Coy JF, Löchelt M. Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 2009; 124:1330-7; http://dx.doi.org/10.1002/ijc.24078; PMID:19065656
107. Zhang S, Yang JH, Guo CK, Cai PC. Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 2007; 253:108-14; PMID:17321041; http://dx.doi.org/10.1016/j.canlet.2007.01.010
108. Kayser G, Kassem A, Sienel W, Schulte-Uentrop L, Mattern D, Aumann K, Stickeler E, Werner M, Passlick B, zur Hausen A. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn Pathol 2010; 5:22; PMID:20385008; http://dx.doi.org/10.1186/1746-1596-5-22
109. Stern R, Shuster S, Neudecker BA, Formby B. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res 2002; 276:24-31; PMID:11978005; http://dx.doi.org/10.1006/excr.2002.5508
110. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011; 71:6921-5; PMID:22084445; http://dx.doi.org/10.1158/0008-5472.CAN-11-1457
111. Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA, Ha PK, Califano JA. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 2010; 16:857-66; http://dx.doi.org/10.1158/1078-0432.CCR-09-2604; PMID:20103683